After surgery for papillary thyroid cancer, treatment with radioactive iodine-131 temporarily increased markers of DNA damage in blood cells, with the highest levels seen one week after treatment and some reduction by six months, but the long-term significance of these changes is unknown.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether I-131 therapy consistently leads to transient increases in DNA damage markers across multiple high-quality studies in PTC patients, and whether these changes correlate with long-term clinical outcomes such as secondary malignancy or mortality.
A systematic review and meta-analysis of all prospective cohort studies and randomized controlled trials comparing DNA damage biomarkers (MN, NPB, 8-OHdG) in PTC patients before and after I-131 therapy, with standardized measurement protocols, minimum follow-up of 5 years, and adjustment for confounders such as age, radiation dose, and surgical history.
Whether I-131 therapy directly causes a measurable increase in DNA damage markers compared to no I-131 therapy in PTC patients after thyroidectomy, controlling for surgical and disease-related variables.
A double-blind, placebo-controlled trial of 300 adults aged 25–70 with low-to-intermediate risk PTC after total thyroidectomy, randomized to receive either 100 mCi I-131 or a sham procedure (no radioactivity), with blood samples collected at baseline, 7 days, 6 months, and 5 years to measure MN, NPB, and 8-OHdG as primary endpoints, and secondary endpoints including thyroid function and secondary cancer incidence.
Whether I-131 exposure in PTC patients is associated with a higher incidence of persistent DNA damage markers or secondary malignancies over a 10-year period compared to matched patients who did not receive I-131.
A prospective cohort study following 1,000 PTC patients after total thyroidectomy, with 500 receiving I-131 and 500 not receiving it, matched for age, tumor stage, and surgical details, with annual measurement of MN, NPB, and 8-OHdG and surveillance for secondary cancers over 10 years.
Whether patients who develop secondary malignancies after PTC treatment are more likely to have received I-131 than those who do not, adjusting for radiation dose and other risk factors.
A case-control study comparing 200 PTC survivors who developed secondary cancers (cases) with 400 matched PTC survivors without secondary cancers (controls), assessing prior I-131 exposure, cumulative radiation dose, and pre-treatment DNA damage biomarkers as exposure variables.
Whether a single measurement of DNA damage markers in PTC patients correlates with prior I-131 exposure at a single time point.
A cross-sectional analysis of 500 PTC survivors, measuring MN, NPB, and 8-OHdG levels in blood samples and correlating them with documented I-131 exposure history, time since treatment, and radiation dose, while controlling for age, smoking, and comorbidities.